ADAPTABLE, the First Fully Decentralized Mega-Trial, Powered by Medidata Technology, Wins Top 10 Clinical Research Achievement Award
Groundbreaking Study by Duke Clinical Research Institute Recognized by The Clinical Research Forum
May 10, 2022—The first fully decentralized clinical mega-trial, supported by Medidata, a Dassault Systèmes company, has earned a Top 10 Clinical Research Achievement Award from the Clinical Research Forum. The ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term Effectiveness) study, led by researchers at the Duke Clinical Research Institute (DCRI), proved that innovative remote technologies could decrease the burden on patients, and increase participation and engagement.
“The ADAPTABLE study, noted in the New England Journal of Medicine as a ‘pivotal’ advancement, provided such valuable insights that it became a foundational trial for many pharmaceutical companies wanting to move to decentralized clinical trials (DCTs),” said Dr. Holly Robertson, senior director Advisory and Enablement Services at Medidata and former project leader at DCRI. “The fact that ADAPTABLE was identified as one of the top 10 influential clinical trials is recognition that its many lessons are having an impact on decentralized trials being designed today.”
ADAPTABLE, noted by researchers as the first trial where the role of the patient shifted from participant to partner, was designed to determine the aspirin dosage for heart disease patients that most effectively maximizes results while minimizing harmful side effects such as internal bleeding. Individuals used the first version of the myMedidata portal, Medidata’s suite of innovative patient-facing technologies focused on enhancing patient centricity and diversity in DCTs.
“When compared with traditional cardiovascular trials that engage hundreds or thousands of sites, this technology allowed us to enroll 15,000 participants from 40 centers,” said Dr. Schuyler Jones, ADAPTABLE co-principal investigator, Associate Professor of Medicine, Duke University Medical Center. Robertson added, “Previously, to enroll a cardiovascular mega-trial, you would need hundreds of clinical sites. Leveraging Medidata’s technology, ADAPTABLE achieved enrollment at a scale never seen before, saving time and money.”
The ADAPTABLE research team was honored at The Clinical Research Forum Annual Meeting in Chicago. The Awards recognize outstanding achievements in clinical research from across the U.S., identifying major advances in the biomedical field resulting from the nation’s investment in health and welfare.
To learn more about Medidata’s support of this important work, visit the Medidata Decentralized Clinical Trials Program page and join the company’s webinar on Medidata’s support of the ADAPTABLE study on June 14. The free webinar will feature Dr. Schuyler Jones, Dr. Holly Robertson, and Michael Tucker, managing partner Patient Cloud at Medidata.
Contact:
Tom Paolella
Senior Director, Corporate Communications & Affairs
+1-848-203-7596
thomas.paolella@3ds.com
Paul Oestreicher
External Communications Director
+1-917-522-4692
paul.oestreicher@3ds.com